VERA Vera Therapeutics Inc
Company Analysis
Latest News
🔴 Vera Therapeutics is trading 4.3% down today amid AI-spending concerns and rising oil prices
Vera Therapeutics is trading 4.3% down at $29.85; no company-specific news clearly explains the decline amid AI-spending concerns and rising oil prices amid...
🟢 Vera Therapeutics is trading at 4.3% up today as investors eye ORIGIN 3 results webcast
Vera Therapeutics is trading 4.3% higher at $31.35, with investors potentially positioning ahead of the October 22 webcast on final ORIGIN 3 results. - Results...
🟢 Vera Therapeutics is trading 4.46% up amid biotech ETF XBI's reported 2.10% gain
Vera Therapeutics is trading at $30.21 (+4.46%) amid stronger biotech-sector sentiment, with XBI reported up 2.10%. - No clear company-specific announcement...
🟢 Vera Therapeutics rises 4.3% — Biotech Sector Rallies on M&A Activity and Anticipation of Key Cancer Data
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector moved higher, fueled by news that...
🟢 Vera Therapeutics is trading 5% up today as biotech sector gains 2.20%
Vera Therapeutics is trading at $28.14, up 5.24%, with the move consistent with biotech-sector strength. - The biotech sector is up 2.20%. - No new...
🔴 Vera Therapeutics is trading 4.02% down with no clear catalyst identified
Vera Therapeutics is trading 4.02% down at $28.68 on October 12, 2026; the specific driver remains unclear. - The S&P 500 was down 0.06% and the Nasdaq...
🔴 Vera Therapeutics is trading 4.03% down today amid biotech-sector weakness
Vera Therapeutics is trading at $29.03, down 4.03%, amid biotech-sector weakness; no clear company-specific announcement explains the decline. - Recent...
🟢 Vera Therapeutics is trading 4% up with no clear company-specific catalyst
Vera Therapeutics is trading at $30.60, up 4.01%, with no clear company-specific catalyst emerging for its October 7, 2026 gain. - Company announcements found...
🔴 Vera Therapeutics is trading 4.3% down today amid biotech weakness
Vera Therapeutics is trading 4.3% down at $28.55 now, with biotech weakness a possible backdrop; no definitive catalyst has been established. - The broader...
🔴 Vera Therapeutics is trading 4.5% down
Vera Therapeutics is trading 4.5% lower at $29.07, with no clear company-specific announcement or report identified to explain the October 5 decline. - The...
Vera Therapeutics to Present Final ORIGIN 3 Results at ASN Kidney Week
Vera Therapeutics will present the final efficacy analysis from its pivotal ORIGIN 3 trial of TRUTAKNA for IgA nephropathy (IgAN) in a late-breaking oral...
🔴 Vera Therapeutics is trading 4.12% down with no clear catalyst identified
Vera Therapeutics is trading 4.12% down at $30.96, and the specific reason for the decline remains unclear. - Available coverage reports no new...
🔴 Vera Therapeutics is trading 7.81% down in pre-market amid broader risk-off conditions
Vera Therapeutics is trading at $30.00, down 7.81% in pre-market on September 28, 2026, versus the September 25 close of $32.54, amid broader risk-off...
🔴 Vera Therapeutics is trading 4.38% down today as crude oil and Treasury yields pressure stocks
Vera Therapeutics is trading 4.38% lower at $34.67 as rising crude oil and Treasury yields weigh on equity valuations. - The Nasdaq Composite is down 1.16% and...
🟢 Vera Therapeutics is trading 4.42% up today; move remains unattributed
Vera Therapeutics is trading 4.42% up at $35.77, with today’s move unattributed. - On September 15, TRUTAKNA met all prespecified ORIGIN 3 endpoints. - Vera...
🟢 Vera Therapeutics is trading 10.3% up today as biotech stocks rally broadly
Vera Therapeutics is trading 10.26% up now at $35.03 as biotechnology stocks rally broadly, with XBI up 2.55% and the Nasdaq Composite up 1.41%. - The move...
🟢 Vera Therapeutics is trading 7% up today as biotech stocks rally
Vera Therapeutics is trading at $34.27 (+7.00%), driven by biotech-sector strength. - The XBI ETF is up 2.55%, supporting sector-wide gains, while the Nasdaq...
🔴 Vera Therapeutics is trading 4.04% down today despite positive TRUTAKNA Phase 3 results
Vera Therapeutics is trading 4.04% down at $32.31 after reversing gains from September 15’s positive TRUTAKNA Phase 3 results. - The ORIGIN 3 study met all...
🟢 Vera Therapeutics is trading 4.46% up today after TRUTAKNA met all Phase 3 endpoints
Vera Therapeutics is trading at $35.57 (+4.46%) after TRUTAKNA met all prespecified endpoints in the final ORIGIN 3 Phase 3 analysis for IgA nephropathy. -...
Vera Therapeutics Reports Positive Final Phase 3 Trial Results for TRUTAKNA in IgAN
Vera Therapeutics announced that its drug, TRUTAKNA™ (atacicept-vymj), met all prespecified endpoints in the final efficacy analysis of the ORIGIN 3 trial for...